In adults with excess weight and high blood fats, a weekly injection of pemvidutide for 48 weeks lowers triglycerides, total cholesterol, and LDL cholesterol by specific percentages, even if body...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

This drug tells the liver to burn more fat and make fewer fat-carrying particles, which drops bad cholesterol and triglycerides in the blood. It works this way even if you don’t lose weight, because it’s acting directly on the liver, not just through weight change.

Most probable mechanism

In Simple Terms

The drug activates two receptors in the liver and brain that together tell the liver to burn more fat and make less of the fatty particles that raise blood fat levels, which lowers triglycerides and cholesterol even without weight loss.

Causal chain

Pemvidutide binds to and activates glucagon receptors on hepatocytes

Supported by evidence

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Recepto...

which leads to

Glucagon receptor activation increases hepatic fatty acid oxidation and reduces de novo lipogenesis

Supported by evidence

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Recepto...

which leads to

GLP-1 receptor activation in the liver suppresses apolipoprotein B-100 synthesis, reducing VLDL particle assembly and secretion

Indirect evidence only

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Recepto...

which leads to

Reduced VLDL secretion lowers circulating triglycerides and LDL cholesterol, as LDL is derived from VLDL metabolism

Supported by evidence

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Recepto...

Evidence from Studies

Supporting (1)

Community contributions welcome

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial

Score: 69

DOI: 10.2337/db24-262-or

Similar Assertions

In adults with overweight or obesity, taking weekly pemvidutide at doses up to 2.4 mg for 48 weeks is linked to only small increases in heart rate and no meaningful changes in blood sugar or HbA1c levels.

83%

In adults with overweight or obesity, a weekly injection of pemvidutide at 2.4 mg for 48 weeks resulted in nearly half of the participants achieving a body mass index below 30 kg/m², which is the clinical threshold for no longer being classified as obese.

82%

In adults with overweight or obesity and at least one related health condition, a weekly injection of pemvidutide for 48 weeks resulted in an average weight loss of 15.6%, compared to 2.2% with a placebo. Over half of those receiving the treatment lost at least 15% of their body weight, and nearly half no longer met the clinical definition of obesity.

80%

In adults with overweight or obesity, taking 2.4 mg of pemvidutide once a week leads to more weight loss than taking 1.2 mg or 1.8 mg weekly, suggesting that higher doses produce greater effects.

79%